Clinical trials: Tremelimumab
Metastatic Thyroid Papillary Carcinoma, Metastatic Thyroid Follicular Carcinoma
Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial
This is a prospective, multi-centre, open label, stratified, exploratory phase II study evaluating the efficacy and safety of durvalumab plus tremelimumab in different cohorts of patients with thyroid cancers.
- Conditions
- Metastatic Thyroid Papillary Carcinoma, Metastatic Thyroid Follicular Carcinoma, Metastatic Thyroid Cancer
- Trial name
- DUTHY (NCT03753919)
- Testing
- Durvalumab, Tremelimumab
- Where
- 15 sites in Spain
- Volunteers
- 79 people
- Sponsor
- Grupo Espanol de Tumores Neuroendocrinos
Invasive Bladder Cancer
Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach
Combined-modality treatment of localized muscle invasive bladder cancer including transurethral resection (TUR), radiotherapy and dual checkpoint inhibition immunotherapy could achieve pathological complete response in some…
- Trial name
- IMMUNOPRESERVE (NCT03702179)
- Testing
- Durvalumab, Tremelimumab, Radiotherapy
- Where
- 7 sites in Spain
- Volunteers
- 32 people
- Sponsor
- Spanish Oncology Genito-Urinary Group
Solid Tumor
A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors
The main purpose of this study is to evaluate the safety of the colony-stimulating factor 1 receptor (CSF-1R) inhibitor LY3022855 in combination with durvalumab or tremelimumab in participants with advanced solid tumors.
- Trial name
- NCT02718911
- Testing
- LY3022855, Durvalumab, Tremelimumab
- Where
- 14 sites in United States, Belgium and 2 more
- Volunteers
- 72 people
- Sponsor
- Eli Lilly and Company
Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV)
Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
Primary objective: To assess the efficacy of various sequences of either a small molecule or an IMT (IMT-A) followed by a IMT-B (MEDI4736) .
- Trial name
- NCT02179671
- Testing
- Gefitinib, AZD9291, Selumetinib+Docetaxel
- Where
- 10 sites in United States
- Volunteers
- 32 people
- Sponsor
- AstraZeneca
Hepatocellular Carcinoma
Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
This is a randomized, open-label, multi-center, global, Phase III study to assess the efficacy and safety of durvalumab plus tremelimumab combination therapy and durvalumab monotherapy versus sorafenib in the treatment of…
- Trial name
- HIMALAYA (NCT03298451)
- Testing
- Durvalumab, Tremelimumab (Regimen 1), Tremelimumab (Regimen 2)
- Where
- 160 sites in United States, Brazil and 15 more
- Volunteers
- 1,324 people
- Sponsor
- AstraZeneca
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma
Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This phase II trial studies how well durvalumab and tremelimumab work in treating participants with ovarian, primary peritoneal, or fallopian tube cancer that has come back or does not respond to treatment.
- Conditions
- Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma
- Trial name
- NCT03026062
- Testing
- Durvalumab, Tremelimumab
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Unresectable Pleural or Peritoneal Malignant Mesothelioma
Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma
This is a Phase 2b, randomized, double-blind, parallel-group study. Subjects with unresectable pleural or peritoneal malignant mesothelioma will be randomized in a 2:1 ratio to receive either tremelimumab or placebo.
- Trial name
- Tremelimumab (NCT01843374)
- Testing
- Tremelimumab
- Where
- 104 sites in United States, Australia and 17 more
- Volunteers
- 571 people
- Sponsor
- MedImmune LLC
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer
This phase I/II trial studies the best dose of selumetinib and how well it works with durvalumab and tremelimumab in treating participants with stage IV non-small cell lung cancer or that has come back.
- Conditions
- Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Trial name
- NCT03581487
- Testing
- Durvalumab, Selumetinib, Tremelimumab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8
Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer
This early phase I trial studies the side effects of durvalumab and tremelimumab before surgery in treating patients with hormone receptor positive, HER2 negative stage II-III breast cancer.
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
- Trial name
- NCT03132467
- Testing
- Durvalumab, Tremelimumab
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center
Gastric or Gastroesophageal Junction Adenocarcinoma
A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma
This is a randomized, multicenter, open-label, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, PK, pharmacodynamics, and immunogenicity of MEDI4736 in combination with…
- Trial name
- NCT02340975
- Testing
- MEDI4736 + tremelimumab, MEDI4736, Tremelimumab
- Where
- 28 sites in United States, Canada and 4 more
- Volunteers
- 114 people
- Sponsor
- MedImmune LLC
Prostate Cancer
CP-675,206 in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer
The current protocol will evaluate the safety of combining treatment with bicalutamide(Casodex) and CP-675,206 (anti-CTLA-4 monoclonal antibody) in patients with PSA-recurrent non-metastatic (stage D0) prostate cancer.
- Trial name
- NCT00702923
- Testing
- Bicalutamide and CP-675,206 (Tremelimumab), Bicalutamide, CP-675,206 (tremelimumab), Bicalutamide, CP-675,206
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Wisconsin, Madison
Non-Transitional Cell Carcinoma of the Urothelial Tract, Small Cell of the Bladder
Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract
This study is being done test to test the safety and effectiveness of durvalumab combined with tremelimumab in patients who have a rare form of cancer of the urinary tract.
- Conditions
- Non-Transitional Cell Carcinoma of the Urothelial Tract, Small Cell of the Bladder, Adenocarcinoma of the Bladder, Squamous Cell Carcinoma of the Bladder
- Trial name
- NCT03430895
- Testing
- durvalumab and tremelimumab
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Melanoma (Skin)
Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma
RATIONALE: Monoclonal antibodies, such as ticilimumab (CP-675,206), can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00471887
- Testing
- CP-675,206
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Recurrent/Metastatic Squamous Cell Carcinoma of Head & Neck
Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck
The purpose of this study is to determine the efficacy and safety of investigational medical products (MEDI4736 monotherapy, tremelimumab monotherapy, and MEDI4736 + tremelimumab combination therapy) in the treatment of patients…
- Trial name
- NCT02319044
- Testing
- MEDI4736, Tremelimumab, MEDI4736 + Tremelimumab
- Where
- 125 sites in United States, Australia and 13 more
- Volunteers
- 267 people
- Sponsor
- AstraZeneca
Non - Small Cell Lung Cancer NSCLC
A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer
This study is a Phase III, randomised, open label, multi-centre study assessing the efficacy and safety of MEDI4736 (durvalumab) versus Standard of Care in NSCLC patients with PD-L1 positive tumours and the combination of…
- Trial name
- ARCTIC (NCT02352948)
- Testing
- MEDI4736 (durvalumab), Vinorelbine, Gemcitabine
- Where
- 201 sites in United States, Australia and 24 more
- Volunteers
- 597 people
- Sponsor
- AstraZeneca
BRCA1 Gene Mutation, BRCA2 Gene Mutation
Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation
This phase I/II trial studies the side effects and best dose of olaparib when give together with durvalumab and tremelimumab and to see how well they work in treating patients with ovarian, fallopian tube, or primary peritoneal…
- Conditions
- BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma
- Trial name
- NCT02953457
- Testing
- Durvalumab, Laboratory Biomarker Analysis, Olaparib
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Roswell Park Cancer Institute
Malignant Glioma, Recurrent Glioblastoma
Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma
The main purpose of this trial is to investigate the effects of a new class of drugs that help the patient's immune system attack their tumor (glioblastoma multiforme - GBM).
- Trial name
- NCT02794883
- Testing
- Durvalumab, Laboratory Biomarker Analysis, Surgical Procedure
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Northwestern University
Endometrial Cancer, Endometrial Carcinosarcoma
A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer
This study will test the safety and efficacy of the experimental drug called durvalumab with or without another experimental drug called tremelimumab in endometrial cancer.
- Conditions
- Endometrial Cancer, Endometrial Carcinosarcoma, Endometrial Carcinoma, Endometrial Cancer Recurrent
- Trial name
- NCT03015129
- Testing
- Durvalumab, Tremelimumab
- Where
- 7 sites in United States
- Volunteers
- 80 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Pancreatic Ductal Adenocarcinoma
Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma
A Phase II Open-Label, Multi-Center Study of MEDI4736 Evaluated as Single Agent or in Combination with Tremelimumab in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.
- Trial name
- NCT02558894
- Testing
- MEDI4736 monotherapy, tremelimumab+MEDI4736
- Where
- 21 sites in United States, Canada and 4 more
- Volunteers
- 65 people
- Sponsor
- AstraZeneca
Prostate Cancer
Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer
The purpose of this study is to find out the effects of giving durvalumab alone or in combination with tremelimumab on this type of cancer.
- Trial name
- NCT02788773
- Testing
- Durvalumab, Tremelimumab
- Where
- 11 sites in Canada
- Volunteers
- 52 people
- Sponsor
- Canadian Cancer Trials Group